{"id":"2ce08083-31fe-51db-8f27-cd554f448e0e","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cib1-typeiii","predicate":"reported_relationship","statement":"CIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"7af0f349-b739-5846-a014-47aafa3a192e","mechanism_event_label":"CIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.","subject":{"id":"423c69cf-f74b-5c98-ae25-59b92f2a98f1","slug":"cib1","display_name":"Human calcium and integrin-binding protein 1 / CIB1","entity_type_key":"protein"},"object":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"7af0f349-b739-5846-a014-47aafa3a192e","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cib1-typeiii-event","event_type":"biochemical_relationship","label":"CIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.","description":"### api-cib1-typeiii\n\nCIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.\nThis study did not test apigenin. Cytosolic and extracellular CD38 topology are not interchangeable.\nModel and exposure: Human myeloma cells and topology-sensitive nanobody assays.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels. | 2017 | https://pubmed.ncbi.nlm.nih.gov/28720704/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5547619/ | https://doi.org/10.1073/pnas.1703718114 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"423c69cf-f74b-5c98-ae25-59b92f2a98f1","slug":"cib1","display_name":"Human calcium and integrin-binding protein 1 / CIB1","entity_type_key":"protein"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"fddfde71-6536-5ac2-82cd-5942ad68b116","slug":"cd38","display_name":"Human CD38","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""},{"entity":{"id":"55ff303e-ae6b-5adf-b34f-a11a53812e9a","slug":"cyclic-adp-ribose","display_name":"Cyclic ADP-ribose","entity_type_key":"small_molecule"},"role":"related measured product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human myeloma cells and topology-sensitive nanobody assays.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"CIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels. | https://pubmed.ncbi.nlm.nih.gov/28720704/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5547619/ | https://doi.org/10.1073/pnas.1703718114","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-cib1-typeiii; This study did not test apigenin. Cytosolic and extracellular CD38 topology are not interchangeable.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"961a01ea-ac87-5747-856a-0efd58a847f9","evidence_kind":"source_excerpt","locator":"Lines 280-286","start_line":280,"end_line":286,"excerpt":"### api-cib1-typeiii\n\nCIB1 interacted with cytosol-facing type-III CD38 in the reported human-cell models.\nThis study did not test apigenin. Cytosolic and extracellular CD38 topology are not interchangeable.\nModel and exposure: Human myeloma cells and topology-sensitive nanobody assays.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels. | 2017 | https://pubmed.ncbi.nlm.nih.gov/28720704/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5547619/ | https://doi.org/10.1073/pnas.1703718114 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Human myeloma cells and topology-sensitive nanobody assays.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}